Jim Simons’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.46M | Buy |
863,187
+513,187
| +147% | +$2.25M | ﹤0.01% | 2064 |
|
|
2025
Q4 | $1.81M | Buy |
350,000
+152,700
| +77% | +$784K | ﹤0.01% | 1924 |
|
|
2025
Q3 | $1.03M | Buy |
197,300
+84,500
| +75% | +$441K | ﹤0.01% | 2467 |
|
|
2025
Q2 | $432K | Sell |
112,800
-3,800
| -3% | -$9.82K | ﹤0.01% | 2910 |
|
|
2025
Q1 | $670K | Sell |
116,600
-50,500
| -30% | -$299K | ﹤0.01% | 2618 |
|
|
2024
Q4 | $834K | Buy |
167,100
+59,700
| +56% | +$306K | ﹤0.01% | 2594 |
|
|
2024
Q3 | $579K | Sell |
107,400
-395,900
| -79% | -$1.88M | ﹤0.01% | 2717 |
|
|
2024
Q2 | $1.67M | Sell |
503,300
-224,390
| -31% | -$879K | ﹤0.01% | 1988 |
|
|
2024
Q1 | $2.38M | Buy |
727,690
+427,690
| +143% | +$1.41M | ﹤0.01% | 1915 |
|
|
2023
Q4 | $1.05M | Buy |
300,000
+78,200
| +35% | +$241K | ﹤0.01% | 2368 |
|
|
2023
Q3 | $1.48M | Sell |
221,800
-83,556
| -27% | -$620K | ﹤0.01% | 2045 |
|
|
2023
Q2 | $2.56M | Buy |
305,356
+57,956
| +23% | +$571K | ﹤0.01% | 1842 |
|
|
2023
Q1 | $2.46M | Buy |
247,400
+33,900
| +16% | +$240K | ﹤0.01% | 1895 |
|
|
2022
Q4 | $1.49M | Sell |
213,500
-164,800
| -44% | -$942K | ﹤0.01% | 2271 |
|
|
2022
Q3 | $2.02M | Sell |
378,300
-135,800
| -26% | -$815K | ﹤0.01% | 1998 |
|
|
2022
Q2 | $2.05M | Buy |
+514,100
| New | +$1.77M | ﹤0.01% | 2169 |
|
|
2021
Q1 | – | Sell |
-53,800
| Closed | -$369K | – | 3280 |
|
|
2020
Q4 | $369K | Buy |
+53,800
| New | +$378K | ﹤0.01% | 2954 |
|
|
2020
Q3 | – | Sell |
-79,618
| Closed | -$332K | – | 3346 |
|
|
2020
Q2 | $332K | Sell |
79,618
-516,782
| -87% | -$1.89M | ﹤0.01% | 3001 |
|
|
2020
Q1 | $1.47M | Buy |
596,400
+517,200
| +653% | +$2.33M | ﹤0.01% | 2220 |
|
|
2019
Q4 | $460K | Buy |
+79,200
| New | +$457K | ﹤0.01% | 2935 |
|
|
2019
Q3 | – | Sell |
-90,200
| Closed | -$541K | – | 3403 |
|
|
2019
Q2 | $541K | Buy |
+90,200
| New | +$679K | ﹤0.01% | 2962 |
|
|
2019
Q1 | – | Sell |
-12,000
| Closed | -$100K | – | 3426 |
|
|
2018
Q4 | $100K | Buy |
12,000
+700
| +6% | +$7.17K | ﹤0.01% | 3232 |
|
|
2018
Q3 | $156K | Sell |
11,300
-11,800
| -51% | -$95.7K | ﹤0.01% | 3190 |
|
|
2018
Q2 | $184K | Sell |
23,100
-7,500
| -25% | -$59.8K | ﹤0.01% | 3084 |
|
|
2018
Q1 | $230K | Sell |
30,600
-31,500
| -51% | -$239K | ﹤0.01% | 3147 |
|
|
2017
Q4 | $422K | Sell |
62,100
-23,100
| -27% | -$152K | ﹤0.01% | 2922 |
|
|
2017
Q3 | $613K | Buy |
85,200
+29,900
| +54% | +$156K | ﹤0.01% | 2736 |
|
|
2017
Q2 | $257K | Buy |
55,300
+29,000
| +110% | +$133K | ﹤0.01% | 2942 |
|
|
2017
Q1 | $132K | Buy |
+26,300
| New | +$135K | ﹤0.01% | 3049 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Jim Simons's ALDX Position: Q1 2026 in Review
Jim Simons increased its Aldeyra Therapeutics (ALDX) stake by 147% in Q1 2026, buying an estimated $2.25M and bringing the position to 863,187 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2064.
Jim Simons first reported a position in ALDX in Q1 2017 and has held it in 29 quarters since. The position peaked at $2.56M in Q2 2023. 128 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Jim Simons held 863,187 shares of Aldeyra Therapeutics worth $1.46M as of Q1 2026.
- Jim Simons bought 513,187 Aldeyra Therapeutics shares in Q1 2026, an estimated $2.25M.
- Aldeyra Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2064 holding.
- Jim Simons first reported a position in Aldeyra Therapeutics in Q1 2017 and has held it in 29 quarters since.
- Jim Simons's Aldeyra Therapeutics position peaked at $2.56M in Q2 2023.
- 128 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.